Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Benjamin Powell

Vascular Surgery Augusta, GA Medical Doctor

NPI 1619210119 CMS profile 1312942

630 13Th St Ste 250, Augusta, GA 30901

Open in the dashboard

General payments

$13,002

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Powell of Augusta, GA is reported in the CMS Open Payments database as having received $13,002 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $148 6
2024 General $828 31
2023 General $563 22
2022 General $638 21
2021 General $193 10
2020 General $5,710 15
2019 General $4,922 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Powell
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Benjamin Powell were reported at $148. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Benjamin Powell Vascular Surgery median Middle half National median
2019 $4,922 $796 $226–$2,363 $163
2020 $5,710 $348 $118–$1,110 $114
2021 $193 $471 $158–$1,421 $132
2022 $638 $725 $222–$2,183 $149
2023 $563 $836 $257–$2,440 $160
2024 $828 $909 $252–$2,619 $164
2025 $148 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $8,313 6 payments
  2. W. L. Gore & Associates, Inc. $2,570 29 payments
  3. Medtronic, Inc. $715 5 payments
  4. Inari Medical, Inc. $578 45 payments
  5. LeMaitre Vascular, Inc. $123 7 payments
  6. Endologix, Inc. $117 1 payment
  7. Organogenesis Inc. $114 4 payments
  8. Cardiva Medical, Inc. $80 3 payments
  9. Silk Road Medical, Inc. $78 4 payments
  10. Maquet Cardiovascular U.S. Sales, L.L.C. $70 2 payments
  11. Other $247 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $7,700 3 payments
  2. Education $2,071 10 payments
  3. Food and Beverage $1,923 103 payments
  4. Consulting Fee $664 3 payments
  5. Travel and Lodging $644 1 payment
Products named General payments · program years 2019–2025
  1. Endurant $7,700 3 payments
  2. VIABAHN VBX Balloon Expandable Endoprosthesis $1,184 6 payments
  3. TAG Thoracic Endoprosthesis $705 8 payments
  4. AMPLATZ GOOSE NECK $624 2 payments
  5. FLOWTRIEVER CATHETER, S $605 46 payments
  6. CT THROMBECTOMY SYSTEM KIT $551 44 payments
  7. ClosureFast $356 1 payment
  8. Vascular Graft $354 3 payments
  9. GORE VIABAHN VBX Balloon Expandable Endo $223 4 payments
  10. AFX2 Bifurcated Endograft System $117 1 payment
  11. Other $1,098 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

273

Median for Vascular Surgery: 122

Drug cost

$60,692

Median for Vascular Surgery: $14,135

Branded share of claims

71.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 45 $39,327
Xarelto Rivaroxaban Brand 24 $19,037
Cilostazol Generic 50 $1,223
Clopidogrel Clopidogrel Bisulfate Brand 87 $821
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $197
Atorvastatin Calcium Generic 11 $67
Prednisone Generic 18 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$637,632

Of which drugs: $205,504

Medicare patients

721

Average age 73

Services billed

12,963

393 women, 328 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 51%
Chronic kidney disease 50%
Ischemic heart disease 39%
Heart failure 33%
Depression 31%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 70 10,005 $1,062

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record